title: Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.
abstract: Adoptive T-cell therapy is delivering objective clinical responses across a number of cancer indications in the early phase clinical setting. Much of this clinical activity is taking place at major clinical academic centers across the United States. This review focuses upon cancer-focused cell therapy activity within the United Kingdom as a contribution to the 2015 British Society of Gene and Cell Therapy annual general meeting. This overview reflects the diversity and expansion of clinical and preclinical studies within the United Kingdom while considering the background context of this work against new infrastructural developments and the requirements of nationalized healthcare delivery within the UK National Health Service.
authors: 1Clinical and Experimental Immunotherapy Group, Institute of Cancer Sciences, The University of Manchester, Manchester M20 4BX, United Kingdom.
authors: David Edward
authors: DE
authors: Gilham
authors: 2UCL Institute of Child Health, London WC1N 1EH, United Kingdom.
authors: John
authors: J
authors: Anderson
authors: 3Cellular Therapeutics Ltd., UMIC Bio-incubator, Manchester M13 9XX, United Kingdom.
authors: John Stephen
authors: JS
authors: Bridgeman
authors: 1Clinical and Experimental Immunotherapy Group, Institute of Cancer Sciences, The University of Manchester, Manchester M20 4BX, United Kingdom.|3Cellular Therapeutics Ltd., UMIC Bio-incubator, Manchester M13 9XX, United Kingdom.
authors: Robert Edward
authors: RE
authors: Hawkins
authors: 4MCCIR, Faculty of Medicine, The University of Manchester, Manchester M13 9NT, United Kingdom.
authors: Mark Adrian
authors: MA
authors: Exley
authors: 5Department of Immunology, University College London, Royal Free Hospital, London NW3 2PF, United Kingdom.
authors: Hans
authors: H
authors: Stauss
authors: 6Department of Research Oncology, Bermondsey Wing, Guy's Hospital, London SE1 9RT, United Kingdom.
authors: John
authors: J
authors: Maher
authors: 7Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, United Kingdom.
authors: Martin
authors: M
authors: Pule
authors: 8Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital, Cardiff CF14 4XN, United Kingdom.
authors: Andrew Kelvin
authors: AK
authors: Sewell
authors: 9School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom.
authors: Gavin
authors: G
authors: Bendle
authors: 9School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom.
authors: Steven
authors: S
authors: Lee
authors: 10Molecular and Cellular Immunology Institute, Institute of Child Health, London WC1N 1EH, United Kingdom.
authors: Waseem
authors: W
authors: Qasim
authors: 10Molecular and Cellular Immunology Institute, Institute of Child Health, London WC1N 1EH, United Kingdom.
authors: Adrian
authors: A
authors: Thrasher
authors: 5Department of Immunology, University College London, Royal Free Hospital, London NW3 2PF, United Kingdom.
authors: Emma
authors: E
authors: Morris
mesh_terms: D000818:Animals; D001709:Biotechnology; D064987:Cell- and Tissue-Based Therapy; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D006113:United Kingdom